All In MedTech

Reimbursement

TCET: Medicare's Transitional Coverage for Emerging Technologies

TCET Medicare coverage explained: which Breakthrough Devices qualify, the five-per-year limit, the timeline, evidence plans, and the 2026 pause for RAPID.

By the All In MedTech editorial team · Published November 19, 2026 · 6 min read

TCET, the Transitional Coverage for Emerging Technologies pathway, is a voluntary Medicare program that aims to shorten the gap between FDA authorization of a Breakthrough Device and national Medicare coverage. CMS finalized it in August 2024. It works by starting the coverage review before FDA acts and by covering the device under an evidence development plan while gaps in the evidence are filled.

The pathway is small by design, limited to about five devices a year, and as of August 2026 it is paused for new candidates while CMS sets up a successor process called RAPID. This post explains how TCET works, who it was built for, and where things stand now.

Why TCET exists

FDA and CMS answer different questions. FDA decides whether a device is safe and effective enough to be marketed. CMS decides whether an item or service is "reasonable and necessary" for Medicare patients, which is the standard in section 1862(a)(1)(A) of the Social Security Act. A device can be cleared or approved and still lack Medicare coverage, because the trials FDA reviewed may not have enrolled many older patients with several conditions, or may not have measured the outcomes CMS cares about.

Without a national decision, coverage for a new device is usually decided locally by Medicare Administrative Contractors, or case by case. That can take years and can differ by region. The difference between national and local coverage is covered in Medicare NCDs vs LCDs.

TCET was CMS's answer after it repealed an earlier rule, Medicare Coverage of Innovative Technology (MCIT), in November 2021. CMS published the TCET final procedural notice in the Federal Register on August 12, 2024 (89 FR 65724), after announcing it on August 7, 2024. The CMS fact sheet on the final notice summarizes the process.

Who is eligible

According to the final notice, a device is an appropriate TCET candidate if it:

  • has FDA Breakthrough Device designation,
  • falls within a Medicare benefit category under Part A or Part B,
  • is not already the subject of an existing national coverage determination (NCD), and
  • is not otherwise excluded from Medicare coverage by statute or regulation.

CMS also said most diagnostic laboratory tests and other in vitro diagnostics should continue through the Medicare Administrative Contractors rather than TCET.

The benefit category requirement matters more than it sounds. Medicare can only pay for items that fit a category defined in the statute, such as a physician service, a hospital service or durable medical equipment. If it is unclear whether a device fits, CMS may run a benefit category review, which can add months. Some software and digital health products may not fit any existing category, which keeps them out of the pathway.

Breakthrough designation itself comes from FDA. The criteria and the list of authorized Breakthrough Devices are covered in the FDA Breakthrough Devices Program.

How the process works

TCET was built around the manufacturer's expected FDA decision date. The main steps in the final notice were:

StepTiming in the final noticeWhat happens
Letter of intent (optional)About 18 to 24 months before expected FDA authorizationNon-binding notice to CMS that a nomination is coming
NominationAbout 12 months before the expected FDA decisionManufacturer submits a self-nomination packet, including the benefit categories it believes apply
CMS reviewQuarterlyCMS meets the manufacturer, consults FDA and decides whether to accept the device. A nomination not selected is carried into the next quarter unless withdrawn
Evidence PreviewAfter acceptanceA contractor runs a focused literature review that grades the existing evidence and lists gaps
Evidence Development PlanBefore the NCD opens, where gaps existManufacturer proposes studies to fill the gaps; CMS and AHRQ review it
Proposed NCDAfter FDA authorizationPosted with a 30-day public comment period
Final NCDCMS goal: within six months of FDA authorizationCoverage begins, usually with coverage with evidence development

CMS said it "anticipates accepting up to five TCET candidates per year," citing its own resources.

Coverage with evidence development

Most TCET coverage was expected to come through coverage with evidence development (CED). Under CED, Medicare covers the device for patients enrolled in an approved study or registry, so that evidence is collected while patients get access. The manufacturer's Evidence Development Plan describes those studies, and the plan can use traditional trials or fit-for-purpose designs, including real-world data.

Transitional coverage was designed to last only as long as it takes to produce the needed evidence. The review date in the plan includes one extra year after study completion for analysis and publication. CMS said that in many cases the whole period would be around five years. At the end, CMS reviews the new evidence and reconsiders the NCD, which may move to coverage without the study requirement, change, or end.

What TCET does not do

TCET is a coverage pathway. It does not set a payment rate and does not create billing codes. The final notice describes coordination with CMS's coding and payment staff, but those decisions still run through their own processes:

  • inpatient hospital stays can receive a New Technology Add-on Payment, covered in NTAP explained,
  • hospital outpatient use can receive transitional pass-through payment,
  • physician services need appropriate procedure codes, which are maintained outside CMS for CPT.

A device can therefore have a national coverage decision and still face coding and payment questions. The broader picture is in how medical device reimbursement works.

What came out of TCET

CMS does not name devices in TCET until an NCD opens. Instead, it publishes counts and dates on its NCD Dashboard. The September 2026 version of the dashboard shows:

  • two NCDs finalized on October 28, 2025, for cardiac contractility modulation in heart failure and renal denervation for uncontrolled hypertension, each marked as a TCET pilot that tested the pathway's processes,
  • an open NCD for a wireless endocardial stimulation system for cardiac resynchronization therapy (WiSE CRT), labeled as a TCET topic,
  • no pending TCET topics.

These are the only TCET-related items the dashboard listed as of that update. Check the dashboard itself for later changes.

The 2026 pause and the RAPID pathway

On April 23, 2026, CMS and FDA announced a new process, the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. CMS then published it as a notice with comment period in the Federal Register on August 11, 2026 (91 FR 51710, file code CMS-3487-NC). Comments were due October 13, 2026.

That notice states that TCET "will be paused for new candidates upon publication of this notice," so TCET has not taken new nominations since August 11, 2026. The notice does not spell out in detail what happens to devices already in TCET; manufacturers in that position should contact CMS directly.

As proposed, RAPID differs from TCET in a few ways:

  • Eligibility: Breakthrough Devices that are Class III, or Class II devices enrolled in FDA's Total Product Life Cycle Advisory Program (TAP), and that are studied under an investigational device exemption (IDE) enrolling Medicare beneficiaries and measuring health outcomes FDA and CMS agree on.
  • Timing: CMS would post a proposed NCD on the same day FDA authorizes the device, with a goal of a final NCD about 60 days later for Class II devices and about 90 days later for Class III devices.
  • Evidence: The idea is to agree on Medicare-relevant outcomes before the pivotal study starts, so the IDE study answers both agencies' questions. IDE studies are explained in Investigational Device Exemption (IDE).

RAPID is not in effect until CMS publishes a final notice. As of November 19, 2026, we had not found a final RAPID notice. Check cms.gov and the Federal Register for the current status before relying on either pathway.

How to follow a device's coverage status

For any specific device, the practical questions are whether it has Breakthrough designation, whether an NCD exists or is open, and what local coverage policies apply in the meantime.

Coverage documents, including NCD tracking sheets and decision memos, are public in the Medicare Coverage Database. A tracking sheet for a former TCET topic lists the dates the nomination was received and accepted and the date the NCD opened.

Frequently asked questions

What is TCET in Medicare?
TCET is a voluntary CMS pathway, finalized in August 2024, that speeds national Medicare coverage for certain FDA Breakthrough Devices by starting the coverage review before FDA authorization and pairing coverage with an evidence development plan.
How many devices can enter TCET each year?
CMS said it anticipates accepting up to five TCET candidates per year.
Is TCET still accepting nominations?
No. CMS paused TCET for new candidates when it published the proposed RAPID coverage pathway in the Federal Register on August 11, 2026.
Does TCET set the payment amount for a device?
No. TCET is about coverage, meaning whether Medicare pays at all. Coding and payment are handled through separate processes such as NTAP for inpatient care and pass-through payment for outpatient care.

For information only, not medical, legal or investment advice. Facts about FDA, CMS and SEC rules are current as of the publication date; check the linked official source for changes.

Keep reading